Skip to main content
HEALIUS LIMITED logo

HEALIUS LIMITED — Investor Relations & Filings

Ticker · HLS ISIN · AU0000033359 LEI · 529900MBZK3SLWK8SJ55 ASX Human health and social work activities
Open in API
Filings indexed 2,292 across all filing types
Latest filing 2022-01-31 M&A Activity
Country AU Australia
Listing ASX HLS

About HEALIUS LIMITED

https://www.healius.com.au

Healius Limited is a leading healthcare service provider specializing in pathology and diagnostic imaging services. The company operates an extensive network of pathology laboratories and collection centers, providing diagnostic testing across various medical disciplines including biochemistry, hematology, and microbiology. Its diagnostic imaging division offers a comprehensive range of services such as X-rays, ultrasounds, CT scans, and MRIs through a network of community-based and hospital-integrated clinics. Healius focuses on delivering high-quality diagnostic insights to healthcare professionals and patients, leveraging advanced technology and a large-scale infrastructure to support clinical decision-making and patient care outcomes.

Recent filings

Filing Released Lang Actions
Completion of Agilex Biolabs acquisition 1 page 469
M&A Activity Classification · 95% confidence The document is an ASX announcement dated 1 February 2022, stating the completion of the acquisition of Agilex Biolabs by Healius. The content focuses on the acquisition event, including the enterprise value and strategic fit, with no financial statements or detailed financial analysis. The document is short (1718 characters) and serves as an announcement of a corporate transaction rather than a full merger filing or detailed merger communication. Therefore, it fits best under the category for announcements related to mergers and acquisitions activity.
2022-01-31 English
Acquisition of Agilex Biolabs 3 pages 502.8KB
M&A Activity Classification · 95% confidence The document is an ASX announcement by Healius Limited regarding the acquisition of Agilex Biolabs. It details the terms of the acquisition, strategic rationale, financial estimates, and includes information about a webcast presentation and conference call related to the announcement. The content focuses on a corporate transaction (acquisition) and does not contain full financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It is not a merger proxy statement or tender offer filing but rather an announcement of a significant corporate transaction. Therefore, the document fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length (7771 characters) and detailed content support this classification with high confidence.
2021-12-16 English
Investor Presentation - Agilex acquisition 14 pages 806.6KB
M&A Activity Classification · 95% confidence The document is a detailed presentation about Healius' acquisition of Agilex Biolabs, including transaction overview, business overview, market overview, strategic rationale, and financial projections. It contains extensive information about the acquisition deal, the business being acquired, market context, and strategic fit. The document is dated December 17, 2021, and is about a merger/acquisition transaction. It is not a full annual or interim report, nor an earnings release or regulatory filing. It is not a proxy or voting announcement. The content is consistent with an M&A Activity announcement or presentation. Given the detailed nature and length (over 14,000 characters), it is more than a simple announcement and fits the M&A Activity category rather than a brief Regulatory Filing or Report Publication Announcement. Therefore, the appropriate classification is M&A Activity (TAR).
2021-12-16 English
Sale of Adora Fertility - termination 1 page 464.7K
Regulatory Filings Classification · 95% confidence The document is an ASX announcement regarding the termination of a sale transaction (Adora Fertility) and mentions the company's intention to continue operating the business. It is a brief announcement about a specific corporate event, not a detailed financial report or presentation. The document length is short (1707 characters), and it does not contain financial statements or detailed analysis. It is not an annual or interim report, nor a call transcript or governance document. It is a regulatory announcement about a corporate transaction update, fitting best under Regulatory Filings (RNS).
2021-12-16 English
Daily share buy-back notice - Appendix 3E 2 pages 166.3KB
Transaction in Own Shares Classification · 100% confidence The document is titled 'Appendix 3E Daily share buy-back notice' and references ASX rules related to share buy-backs. It provides detailed information about the number of shares bought back, total consideration paid, prices paid, and compliance statements. This is a formal notice regarding the company's share repurchase activity. The document length is relatively short (2699 characters), and it contains specific transactional data about share buy-backs rather than a general report or announcement. Therefore, it fits the category of a report on the company's transactions in its own shares (share repurchase). According to the filing definitions, this corresponds to 'Transaction in Own Shares' (POS).
2021-11-30 English
Final share buy-back notice - Appendix 3F 2 pages 233.7KB
Transaction in Own Shares Classification · 95% confidence The document is titled 'Appendix 3F Final share buy-back notice' and contains detailed information about the company's share buy-back activity, including the number of shares bought back, total consideration paid, price range, and compliance statements. It is a formal notice related to the company's repurchase of its own shares. The document length is 1734 characters, which is relatively short but contains substantive details about the buy-back transaction itself, not just an announcement of a report. This fits the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. There is no indication that this is a general regulatory filing or a report publication announcement. Therefore, the correct classification is POS with high confidence.
2021-11-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.